UNC and Emory Researchers Reverse HIV Latency, Important Scientific Step Toward Cure

UNC-Chapel Hill HIV researchers David Margolis, MD, and J. Victor Garcia, PhD, along with Rick Dunham from ViiV Healthcare (from left to right), photographed in UNC Genetic Medicine Building

“Overcoming HIV latency – induction of HIV in CD4+ T cells that lay dormant throughout the body – is a major step toward creating a cure for HIV. For the first time, scientists at UNC-Chapel Hill, Emory University, and Qura Therapeutics – a partnership between UNC and ViiV Healthcare – have shown that a new approach can expose latent HIV to attack in two different animal model systems with little or no toxicity.”

This story first appeared January 22, 2020 on the UNC Healthcare and School of Medicine Newsroom. 

CFAR Investigators named Highly Cited Researchers by Web of Science

Headshots of Gillings faculty members named Highly Cited Researchers (FROM LEFT TO RIGHT TOP: DR. RALPH BARIC, DR. NOEL BREWER, DR. MYRON COHEN, DR. STEPHEN COLE MIDDLE: DR. KELLY EVENSON, DR. DAVID MARGOLIS, DR. HANS PAERL BOTTOM: DR. BARRY POPKIN, DR. KURT RIBISL, DR. JASON SURRATT)CFAR Investigators Drs. Cohen, Margolis, and Cole, along with 7 other Gillings School of Global Public Health faculty members, were recently named Highly Cited Researchers, according to the Highly Cited Researchers 2019 list from the Web of Science Group. This list includes investigators who produced multiple papers ranking in the top 1% by citations for their field and year of publication, demonstrating significant research influence among their peers.

Read more at the Gillings School News. 

National Geographic selects the multinational HPTN 052 HIV trial, led by Myron Cohen, MD, as one of the discoveries of the decade

Mike Cohen Headshot“National Geographic published an article about the top 20 scientific discoveries on the decade, including  the treatment of HIV as prevention, a concept based on Myron Cohen’s multinational HPTN 052 trial, which demonstrated that antiretroviral treatment of people with HIV infection prevents the sexual transmission of the virus. This study served as the basis for HIV “treatment as prevention” programs worldwide and it was recognized by Science Magazine as the “Breakthrough of the Year” in 2011.”

See more here at the UNC Healthcare and UNC School of Medicine Newsroom. Dr. Cohen is the Associate Director of the UNC CFAR and the Associate Director of the CFAR International Core. He also serves as the Associate Vice Chancellor for Global Health and Medical Affairs at UNC-Chapel Hill; the Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology; and Director of the UNC Institute for Global Health & Infectious Diseases.

UNC awarded $2.91 million to create new ultra-long-acting HIV drug delivery implant

“Doctoral students Katie Mollan, MS and Bonnie Shook-Sa, MAS, along with Michael Hudgens, PhD, professor of biostatistics at the UNC Gillings School of Global Public Health, are part of an investigative team that recently received a $2.91 million award from the Bill & Melinda Gates Foundation to create an ultra-long-acting implant for HIV drug delivery.

The principal investigator is J. Victor Garcia, PhD, professor of medicine at UNC-Chapel Hill. Center for AIDS Research (CFAR) biostatisticians Mollan and Shook-Sa will provide statistical expertise and guidance for this study, with mentorship from Hudgens.”

This story first appeared December 2, 2019 on the UNC Gillings School News page. 

Adimora Elected to National Academy of Medicine

ada adimora headshot

Adaora Adimora, MD, MPH, the Sarah Graham Kenan Distinguished Professor of Medicine at the UNC School of Medicine and professor of epidemiology with the UNC Gillings School of Global Public Health, has been elected to the National Academy of Medicine (NAM), widely considered one of the highest honors in the fields of health and medicine. The academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service throughout their careers.

This story first appeared October 29, 2019 on the UNC Health Care and UNC School of Medicine Newsroom.

UNC Awarded $19.4 million to Continue National Effort to Combat HIV Comorbidities

ada adimora headshotResearchers at the University of North Carolina at Chapel Hill will receive $19.4 million over the next seven years to continue their research on chronic illnesses that often accompany HIV infection, including cardiovascular and lung diseases, diabetes, and cancers. Almost half of people with HIV in the United States are over the age of 50 and are more likely to suffer chronic HIV-related comorbidities than infectious complications. The National Institutes of Health (NIH) selected UNC-Chapel Hill as one of the 13 Multicenter AIDS Cohort Study / Women’s Interagency HIV Study Combined Cohort Study (MACS/WIHS-CCS) sites after a competitive application process.

The MACS/WIHS-CCS is a collaborative research effort to understand and reduce the impact of chronic health conditions that affect people living with HIV. Adaora Adimora, MD, MPH, leads the UNC-Chapel Hill site, one of 13 across the country.

This story first appeared on October 14, 2019 on the UNC Health Care and UNC School of Medicine Newsroom.

UNC Gillings School launches Zambia Hub

Group photo in ZambiaThe students, faculty and staff of the UNC Gillings School work in more than 60 countries to address urgent global health challenges. Now, with the launch of a new global hub in Zambia, they have even more opportunities to engage — and this is just the beginning. The UNC CFAR’s International Core worked collaboratively with the UNC Gillings School of Global Public Health to help launch the Zambia hub.

This story appeared first on October 11, 2019 on the UNC Gillings School of Public Health News page. 

Surprise Finding About HIV Reservoir Could Lead to Better Therapies

Swanstrom Headshot LargeResearchers led by Ron Swanstrom, PhD, and colleagues in South Africa, discovered that the latent HIV reservoir that persists during antiretroviral treatment mostly reflects viruses present in the blood at the start of antiretroviral treatment.

“This comes as a big surprise,” said co-senior author Ronald Swanstrom, PhD, professor of biochemistry and biophysics at the UNC School of Medicine. “Our work suggests that if we could understand the reservoir-forming process better, we might be able to intervene at the start of treatment to reduce the majority of the reservoir that forms at this time.”

Read more about this at the UNC Health Care and UNC School of Medicine Newsroom.